Lappoxo

Omeprazole, the active ingredient in Lappoxo, is a proton pump inhibitor presented as an oral tablet for oral use. It reduces gastric acid secretion and is used to treat acid‑related disorders such as gastro‑oesophageal reflux disease, peptic ulcer disease, Helicobacter pylori eradication regimens and erosive esophagitis in adult patients.

GNH USA supplies Lappoxo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole acts on the gastric acid secretion pathway and is indicated for several acid‑related conditions.

- Gastro‑oesophageal reflux disease (GERD): reduces acid exposure, relieving heartburn and regurgitation. - Peptic ulcer disease: promotes ulcer healing by maintaining a higher gastric pH. - Helicobacter pylori eradication: enhances the effectiveness of antibiotic regimens by suppressing gastric acid. - Erosive esophagitis: facilitates mucosal healing and symptom relief.

Omeprazole is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: discomfort in the upper abdomen. - Diarrhoea: loose stools occurring intermittently. - Nausea: feeling of queasiness. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis presenting with watery diarrhoea. - Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: extensive skin detachment. - Hepatic enzyme elevation: increased ALT/AST levels. - Acute interstitial nephritis: renal inflammation with reduced function. - Bone fracture risk: increased incidence with long‑term use.

Before initiating therapy, consider the following safety measures.

- Assess renal function: adjust use in patients with severe impairment. - Review concomitant medications: avoid known CYP2C19 inhibitors that may raise omeprazole levels. - Monitor breakthrough symptoms: consider dose escalation if acid control is inadequate. - Use cautiously in the elderly: higher risk of fractures and electrolyte disturbances. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Omeprazole can affect the pharmacokinetics of several drugs.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, increasing cardiovascular risk. - Atazanavir: decreased absorption, compromising HIV therapy. - High‑dose methotrexate: increased toxicity due to reduced clearance.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR, requiring closer coagulation monitoring. - Diazepam: elevated plasma concentrations, may enhance sedation. - Digoxin: possible increase in serum levels, necessitating dose adjustment.